PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Feb 6, 2015
SOUTH PLAINFIELD, N.J., Feb. 6, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 6, 2015 it approved non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ne...
Feb 5, 2015
SOUTH PLAINFIELD, N.J., Feb 5, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: 2015 Leerink Global Healthcare Conference at the Waldorf Astoria in New York on Thursday, February 12th RBC 2015 Capital Markets' Global Healthcare C...
Jan 7, 2015
SOUTH PLAINFIELD, N.J., Jan. 7, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15th at 11:00 am PT at the Westin St. Francis in San Francisco. The presentation will be webcast live on the Events ...
Jan 2, 2015
SOUTH PLAINFIELD, N.J., Jan. 2, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 2, 2015 it approved non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new...
Dec 23, 2014
SOUTH PLAINFIELD, N.J., Dec. 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). A rolling sub...
Dec 19, 2014
SOUTH PLAINFIELD, N.J., Dec. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I). MPS I...
Dec 17, 2014
SOUTH PLAINFIELD, N.J., Dec. 17, 2014 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ne...
Dec 3, 2014
SOUTH PLAINFIELD, N.J., Dec. 3, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week.   "The launch of Translarna in Germany ma...
Nov 21, 2014
SOUTH PLAINFIELD, N.J., Nov. 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz, Ph.D., Chief Executive Officer. This award recognizes an individual who has had a significant impact on the technology i...
Nov 19, 2014
SOUTH PLAINFIELD, N.J., Nov. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue